NEW YORK (GenomeWeb) – Invitae has launched its initial public offering at $16 per share.

The San Francisco-based molecular diagnostics firm offered 6,350,000 shares of its common stock, bringing in gross proceeds of $101.6 million. It also has granted the underwriters a 30-day option to purchase up to an additional 952,500 shares.

The offering price is above a range of $13 to $15 per share put forth in a preliminary prospectus filed two weeks ago. It also increased the number of shares offered from a previous expectation of 5,350,000.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.